Neonatal Hyperinsulinemic Hypoglycaemia: Diazoxide and Octreotide Therapy

Neonatal hyperinsulinaemic hypoglycaemia occurs when insulin secretion remains inappropriately high for a baby’s blood glucose concentration. Insulin drives glucose into cells, suppresses the release of stored glucose and limits ketone production, leaving the brain with too little fuel. The condition may be transient after fetal growth restriction, maternal diabetes or perinatal stress, or it may reflect congenital hyperinsulinism caused by an inherited change in pancreatic beta-cell function. Learn more about Neonatal Vaccination Schedules In Asia And Oceania.

Treatment needs to protect the brain while clinicians establish the underlying diagnosis. Intravenous dextrose, frequent feeds and careful monitoring are often needed at the beginning. Diazoxide is usually the preferred medication when the infant is likely to respond, while octreotide may be considered when diazoxide is ineffective or unsuitable. These medicines require neonatal, endocrine and pharmacy oversight, especially in Australian hospitals where transfer between regional services and tertiary centres can affect monitoring arrangements.

Recognising Persistent Insulin Excess

A low plasma glucose concentration is more concerning when it occurs with detectable insulin or C-peptide, suppressed ketones and free fatty acids, and a strong glucose response to glucagon. In practice, the “critical sample” should be collected during hypoglycaemia before treatment changes the biochemical picture. It may include laboratory glucose, beta-hydroxybutyrate, free fatty acids, insulin, C-peptide, cortisol, growth hormone, lactate, blood gas and relevant metabolic tests.

The clinical signs can be subtle. Poor feeding, jitteriness, lethargy, apnoea, temperature instability or seizures may be attributed to prematurity or difficult transition after birth. A baby who needs an unusually high glucose infusion rate to maintain safe levels deserves prompt assessment for hyperinsulinism. Persistent requirements above the expected neonatal range, recurrent lows during fasting, or hypoglycaemia after feeds should prompt discussion with a neonatal endocrinology team.

In Australia, care may begin in a local maternity unit in regional New South Wales, Queensland or Western Australia before retrieval to a tertiary neonatal intensive care unit in Sydney, Brisbane, Perth or Melbourne. Retrieval planning should include a reliable dextrose infusion, documented glucose trends and communication with the receiving team. Families may also need practical support when one parent remains near a metropolitan hospital while other children stay at home.

Diazoxide As Initial Medical Treatment

Diazoxide opens ATP-sensitive potassium channels in pancreatic beta cells, stabilising the cell membrane and reducing insulin release. It is generally used when congenital hyperinsulinism is suspected and there is no immediate indication for surgery. A response may be assessed through lower glucose infusion needs, stable pre-feed concentrations and the ability to extend feeding intervals without recurrent hypoglycaemia.

The dose is prescribed by the treating specialist and adjusted according to response, age, weight, renal function and the suspected genetic subtype. Diazoxide can cause sodium and fluid retention, so a thiazide diuretic such as chlorothiazide is often given alongside it. Clinicians monitor weight, fluid balance, electrolytes, urine output and respiratory status. A baby with rising oxygen requirements or signs of pulmonary oedema needs urgent review.

Pulmonary hypertension is a serious but uncommon adverse effect associated with diazoxide. Many centres obtain an echocardiogram before treatment or soon after starting it, particularly when the infant is premature, has respiratory disease or has other risk factors. Other recognised effects include hypertrichosis, neutropenia, thrombocytopenia, reduced appetite and gastrointestinal symptoms. Families should receive clear instructions about doses, missed feeds and when to seek emergency help.

The Australian product supply, hospital formulary and access pathway can differ between states and territories. A neonatal pharmacist can help families understand the formulation dispensed, while the endocrine team should provide a written sick-day and feeding plan. Breast milk remains valuable when safe and feasible, but expressed milk volumes may not be sufficient to meet a baby’s glucose needs during acute treatment.

When Octreotide Enters The Plan

Octreotide is a somatostatin analogue that suppresses insulin secretion through several hormonal pathways. It is generally considered when diazoxide fails, when testing suggests diazoxide-unresponsive congenital hyperinsulinism, or when a temporary bridge is needed before surgery or a more definitive treatment. It may be delivered by intermittent subcutaneous injection or continuous infusion under specialist direction.

Response is judged through glucose stability, reduced dextrose requirements and the capacity to manage feeds safely. Octreotide has a relatively short action, so glucose can change quickly when doses are delayed or stopped. Treatment plans therefore need clear observation periods, access to rescue glucose and reliable handover between neonatal, endocrine and community teams.

Important adverse effects include gastrointestinal disturbance, altered gallbladder function, reduced gut motility and changes in thyroid or other hormone regulation. There is particular concern about intestinal complications in very premature infants, including a possible association with necrotising enterocolitis. For that reason, many clinicians use octreotide cautiously in preterm babies and reassess the risk-benefit balance frequently.

Feeding, Monitoring And Family Care

Medication does not replace a dependable nutrition plan. Some infants need scheduled breast, expressed-milk or formula feeds, while others require continuous enteral feeding or intravenous glucose. The aim is to avoid prolonged fasting and maintain a steady supply of carbohydrate. A dietitian can help calculate energy and carbohydrate intake without creating excessive volume or feeding stress.

Continuous glucose monitoring may support trend recognition in selected infants, but it should not replace laboratory or validated bedside glucose measurements when treatment decisions are made. Sensors can lag during rapidly changing glucose levels, and accuracy in very small babies may vary. Families should know which device readings require confirmation and how often conventional checks will be performed.

Breastfeeding support needs to be culturally safe and realistic. When a parent has suspected or confirmed COVID-19, infection-control advice, hand hygiene, masking policies and expressed-milk arrangements should be coordinated with the hospital; broader breastfeeding guidance can provide useful background, although the infant’s glucose plan remains individualised. In Melbourne, Adelaide or Darwin, local lactation services may be available through the hospital, but access can be different for families travelling from remote communities.

The discharge plan should state the target glucose range, medication times, feeding intervals, glucose-check schedule and emergency actions. It should also identify who to call after hours. Parents need practice using the glucose meter, recognising poor feeding or abnormal behaviour, and giving rescue carbohydrate if instructed. A written plan is especially important around public holidays, long drives and air travel between Australian cities.

Daily Safety Checks

• Confirm each dose against the current weight and prescription.
• Record feeds, glucose results, vomiting and unusual sleepiness.
• Watch for breathing changes, swelling or rapid weight gain.
• Keep prescribed rescue glucose and emergency contacts available.

Specialist Review Points

• Reassess treatment after recurrent low glucose or a rising dextrose need.
• Review genetic results and the likely congenital hyperinsulinism subtype.
• Check whether medication adverse effects outweigh ongoing benefit.
• Coordinate endocrine, neonatal, dietetic and surgical follow-up.

Long-Term Diagnosis And Definitive Decisions

Congenital hyperinsulinism has several genetic forms, and the response to diazoxide can help guide classification. Genetic testing may identify changes affecting the potassium channel, glucokinase or other pathways. A negative result does not exclude the diagnosis, and interpretation should be linked to the clinical course, imaging and treatment response rather than treated as a stand-alone answer.

Some children achieve control with medication and gradually tolerate longer intervals between feeds. Others have persistent disease that requires a specialist surgical assessment. In selected cases, imaging such as fluorine-18 DOPA positron emission tomography may help distinguish focal from diffuse pancreatic disease, although availability is limited and decisions are made through expert centres. Surgery can be curative for a focal lesion, while diffuse disease may require a more complex balance between glucose control and pancreatic function.

Neurodevelopmental follow-up matters because recurrent or prolonged neonatal hypoglycaemia can affect learning, movement, vision and behaviour. Early intervention services, audiology, ophthalmology and developmental paediatrics may be involved. Australian families may encounter different referral pathways through state-funded services, private providers or the National Disability Insurance Scheme, depending on eligibility and location. Keeping copies of admission summaries and pathology results helps when moving between hospitals or seeing a new specialist.

Parents often worry that every brief low reading represents permanent injury. Clinicians can explain the duration and severity of episodes, the treatment response and the child’s developmental progress without offering false reassurance. Regular review should cover growth, feeding, medication tolerance and developmental milestones, with the schedule adjusted as the condition evolves.

A coordinated plan gives families the best chance of avoiding repeat emergencies. Ask the treating neonatal or paediatric endocrinology team for an up-to-date written regimen covering diazoxide or octreotide, glucose checks, feeding intervals, travel, illness and emergency admission. For families preparing to leave a tertiary centre in Brisbane, Perth or elsewhere, arranging local follow-up before the journey can make ongoing care safer and faster.